| Literature DB >> 32227625 |
Meng Zhang1, Panpan Hao1, Chenyu Jiang2, Guoxiang Hao3, Bin Li4, Peixin Hu4, Qingjie Chen5, Yuguo Chen1, Aifeng Zhang6, Yun Zhang1, Yanping Liu7.
Abstract
No study has evaluated the impact of different iodinated contrast media on coronary contrast enhancement, using an injection protocol according to body surface area (BSA). Thus, the present study aimed to examine the usefulness and safety of personalized application of different iodine concentrations of contrast media in coronary computed tomographic (CT) angiography with a 2nd dual-source CT scanner in eliminating differences in coronary contrast enhancement based on a BSA-adapted injection protocol of contrast media. A total of 270 enrolled participants were randomly assigned to three groups: ioversol 320, ioversol 350 and iopromide 370 (n = 90 per group). The three groups were administered contrast media at a BSA-adjusted volume and flow rate with a fixed injection time of 15 seconds, and they subsequently received a 30-mL saline flush. All patients were scanned with a prospective electrocardiogram-gated protocol in a craniocaudal direction using a second-generation 128-slice dual-source CT system. The three iodinated contrast media used in coronary CT angiography exhibited similar diagnostic quality and safety. No significant differences were found in the contrast enhancement degrees, image quality scores, radiation doses and incidences of adverse effects among the three groups. The three contrast media used in coronary CT angiography with 320, 350 and 370 mg/mL iodine, respectively, have comparable diagnostic quality and safety. However, more large-scale, multinational, multi-centre and prospective trials are warranted.Entities:
Keywords: body surface area; contrast media; coronary CT angiography
Year: 2020 PMID: 32227625 PMCID: PMC7214158 DOI: 10.1111/jcmm.15196
Source DB: PubMed Journal: J Cell Mol Med ISSN: 1582-1838 Impact factor: 5.310
Contrast agent protocols used in the three groups
| Iodine concentration (mg/mL) | Volume (mL) | Flow rate (mL/s) | Fixed injection time (s) |
|---|---|---|---|
| 370 (Iopromide) | 31.5BSA | 2.1BSA | 15 |
| 350 (Ioversol) | 33.3BSA | 2.2BSA | 15 |
| 320 (Ioversol) | 36.5BSA | 2.4BSA | 15 |
Abbreviation: BSA, body surface area.
Basic characteristics of the participants
| Iopromide 370 | Ioversol 350 | Ioversol 320 |
| |
|---|---|---|---|---|
| n (Male/Female) | 90 (48/42) | 90 (45/45) | 90 (52/38) | >.05 |
| Mean age (years) | 52.79 | 51.77 | 53.74 | >.05 |
| Mean weight (kg) | 70.92 | 70.71 | 70.07 | >.05 |
| Mean height (cm) | 166.43 | 167.21 | 165.04 | >.05 |
| Mean BMI (kg/m2) | 25.50 | 25.29 | 24.71 | >.05 |
| Mean BSA (m2) | 1.81 | 1.81 | 1.79 | >.05 |
| Mean heart rate (bpm) | 66.68 | 67.62 | 69.92 | >.05 |
| Mean SBP (mm Hg) | 136.03 | 136.14 | 136.28 | >.05 |
| Mean DBP (mm Hg) | 84.17 | 83.69 | 84.07 | >.05 |
Abbreviations: BMI, body mass index; BSA, body surface area; DBP, diastolic blood pressure; SBP, systolic blood pressure.
Coronary artery attenuation
| Mean CT (HU) | Iopromide 370 | Ioversol 350 | Ioversol 320 |
|
|---|---|---|---|---|
| Noise | 21.14 | 21.43 | 21.86 | >.05 |
| Ascending aorta | 473 | 485 | 485 | >.05 |
| RCA | 443 | 453 | 446 | >.05 |
| LM | 476 | 466 | 472 | >.05 |
| LAD | 457 | 455 | 451 | >.05 |
| LCX | 429 | 441 | 432 | >.05 |
Abbreviations: LAD, left anterior descending artery; LCX, left circumflex; LM, left main coronary artery; RCA, right coronary artery.
Image quality scores in the three groups
| Iopromide 370 | Ioversol 350 | Ioversol 320 |
| |
|---|---|---|---|---|
| Mean image quality score | 4.16 | 4.13 | 4.11 | >.05 |
FIGURE 1Coronary sinus imaging in the three groups
FIGURE 2Proximal coronary imaging in the three groups
FIGURE 3Coronary artery trunk imaging in the three groups
Contrast agent volumes and flow rates in the three groups
| Iopromide 370 | Ioversol 350 | Ioversol 320 |
| |
|---|---|---|---|---|
| Mean volume (mL) | 56.98 | 60.20 | 65.21 | <.05 |
| Mean flow rate (mL/s) | 3.80 | 4.01 | 4.35 | <.05 |
FIGURE 4Quantification of the contrast agent volumes and flow rates in the three groups. **P < .01
Radiation dose assessment in the three groups
| Iopromide 370 | Ioversol 350 | Ioversol 320 |
| |
|---|---|---|---|---|
| Mean DLP (mGy*cm) | 302.34 | 292.12 | 290.08 | >.05 |
| Mean ED (mSv) | 4.23 | 4.09 | 4.06 | >.05 |
Abbreviations: DLP, dose‐length product; ED, effective radiation dose.